$307 Million is the total value of Essex Woodlands Management, Inc.'s 7 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDXG | MIMEDX GROUP, INC. | $195,393,076 | -10.0% | 28,195,249 | 0.0% | 63.71% | +1.2% | |
| BVS | BIOVENTUS | $74,872,613 | +10.6% | 13,021,324 | 0.0% | 24.41% | +24.3% | |
| TELA | TELA BIO, INC. | $19,320,332 | -17.1% | 4,110,709 | 0.0% | 6.30% | -6.8% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $13,498,233 | -57.9% | 1,551,521 | 0.0% | 4.40% | -52.7% | |
| MNOV | MEDICINOVA INC | $1,592,555 | -0.7% | 1,105,941 | 0.0% | 0.52% | +11.6% | |
| RVNC | REVANCE THERAPEUTICS INC | $1,174,708 | -47.8% | 457,085 | 0.0% | 0.38% | -41.3% | |
| VENUS CONCEPT, INC. | $852,836 | +13.3% | 1,089,190 | 0.0% | 0.28% | +27.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDICINOVA INC | 45 | Q2 2024 | 6.5% |
| REVANCE THERAPEUTICS INC | 42 | Q2 2024 | 44.6% |
| AXOGEN INC | 26 | Q4 2021 | 43.3% |
| ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
| ABIOMED INC | 20 | Q1 2018 | 52.1% |
| CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
| TELA BIO, INC. | 19 | Q2 2024 | 31.5% |
| VENUS CONCEPT, INC. | 17 | Q4 2023 | 21.3% |
| EYEPOINT PHARMACEUTICALS INC | 15 | Q2 2024 | 27.6% |
| ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.